Ciclesonide
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Ciclesonide: From Asthma / Allergic Rhinitis to Atopic Eczema
One-Sentence Summary
Ciclesonide is a second-generation inhaled corticosteroid (ICS) clinically established for asthma and allergic rhinitis, acting via its active metabolite des-ciclesonide to suppress glucocorticoid receptor-mediated airway inflammation. The TxGNN model predicts it may be effective for Atopic Eczema (score 99.96%), yet there are currently no registered clinical trials and no direct supporting publications for this specific application. While the mechanistic rationale is scientifically plausible, the absence of a topical skin formulation represents a critical route-compatibility gap that must be addressed before clinical development can proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (not marketed in India; standard global use: asthma, allergic rhinitis) |
| Predicted New Indication | Atopic Eczema |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Ciclesonide is a prodrug that is converted by airway esterases into its pharmacologically active form, des-ciclesonide, following inhalation. Des-ciclesonide binds with high affinity to glucocorticoid receptors (GR), triggering suppression of pro-inflammatory gene transcription. This specifically downregulates IL-4, IL-13, and TSLP — the core cytokines driving Th2-polarised immune activation.
Atopic eczema (atopic dermatitis) is fundamentally a Th2-skewed inflammatory disease: its pathophysiology is driven by exactly the same IL-4/IL-13/TSLP axis that des-ciclesonide suppresses. This mechanistic alignment is not incidental — it is the reason why topical corticosteroids (TCS) are the established first-line therapy for atopic dermatitis worldwide, lending strong biological plausibility to the TxGNN prediction.
However, the current gap is practical rather than mechanistic: ciclesonide exists only as an inhaled aerosol and intranasal spray, with no approved dermatological formulation. Realising this prediction would require either a purpose-built topical reformulation of ciclesonide, or evaluation of an alternative systemic route — both of which demand dedicated pharmacokinetic, safety, and efficacy studies before any clinical trial could proceed.
Clinical Trial Evidence
Currently no related clinical trials registered for Ciclesonide in Atopic Eczema.
Literature Evidence
Currently no related literature available for Ciclesonide in Atopic Eczema.
India Market Information
Ciclesonide is not currently marketed in India and holds no product registrations with the Indian regulatory authority (CDSCO). No authorization records are available.
Safety Considerations
Drug Interactions — 63 interactions identified (DDInter database):
| Interacting Drug | Severity |
|---|---|
| Cladribine | Major |
| Clarithromycin | Moderate |
| Cobicistat | Moderate |
| Atazanavir | Moderate |
| Fosamprenavir | Moderate |
| Amprenavir | Moderate |
| Boceprevir | Moderate |
| Ceritinib | Moderate |
| Conivaptan | Moderate |
| Fostamatinib | Moderate |
| Miconazole | Moderate |
| Insulin human (inhalation, rapid acting) | Moderate |
| Abametapir (topical) | Moderate |
| Formoterol | Minor |
| Salbutamol | Minor |
| Arformoterol | Minor |
The most significant interaction is with Cladribine (Major), likely reflecting immunosuppression compounding. Multiple CYP3A4 inhibitors (clarithromycin, cobicistat, HIV protease inhibitors) are flagged at moderate severity, consistent with ciclesonide’s known CYP3A4-dependent metabolism.
Key warnings and contraindications data are not available in the current evidence pack. Please refer to the official package insert (EMA/US FDA SmPC) for complete safety and contraindication information.
Conclusion and Next Steps
Decision: Hold
Rationale: Although TxGNN’s prediction is mechanistically coherent — the Th2/GR pathway alignment between ciclesonide’s pharmacology and atopic eczema’s pathophysiology is genuine — there is zero clinical or published evidence specifically supporting this use, and ciclesonide’s existing formulations are incompatible with dermatological application. The route-compatibility gap is a blocking prerequisite, not a minor detail.
To proceed, the following is needed:
- Formulation feasibility: Determine whether ciclesonide can be reformulated as a topical skin preparation (cream/ointment), or whether an oral/systemic route could be justified for moderate-to-severe atopic dermatitis
- Preclinical data: Commission skin penetration studies and in vitro/in vivo atopic dermatitis model testing with reformulated ciclesonide
- MOA documentation: Retrieve complete mechanism of action data from DrugBank (DB01410) to formalise the mechanistic dossier
- Regulatory safety review: Download and parse the EMA/FDA package insert to extract key warnings, contraindications, and special population restrictions
- Competitive context analysis: Evaluate differentiation opportunity against widely available generic topical corticosteroids (e.g., hydrocortisone, betamethasone) and newer biologics (dupilumab) in the atopic dermatitis market
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.